Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | MRD using multi-parametric flow cytometry in AL amyloidosis

Andrew Staron • 10 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Andrew Staron, MD, Boston Medical Centre, Boston, MA, discusses the assessment of minimal residual disease (MRD) using multiparametric flow cytometry in treated patients with AL amyloidosis. This is a powerful analytical and preparative tool that enables the rapid measurement of multiple physical and chemical characteristics of individual cells and may allow for increased accuracy in patient stratification. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Staron

2:13
Advances & unanswered questions about the role of MRD in AL amyloidosis
Andrew Staron • 5 Sep 2022
1:53
The prognostic role of MRD in AL amyloidosis
Andrew Staron • 5 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals